ICH Safety Guidelines
ICH has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability: the single most important cause of drug withdrawals in recent years.
Click on the titles below for complete guidelines
S1A - S1C Carcinogenicity Studies
S3A - S3B Toxicokinetics and Pharmacokinetics
S7A - S7B Pharmacology Studies
S9 Nonclinical Evaluation for AnticancerPharmaceuticals
S11 Nonclinical Paediatric Safety
S12 Non-clinical Biodistribution Studies for Gene Therapy Products
ICH Safety Guidelines from S1A to S12